Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5526_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Contents
- •1.1 Introduction
- •1.2 Pathophysiology
- •1.3 Case Presentation
- •1.4 Case Discussion
- •1.5 Clinical Characteristics
- •1.6 Diagnostic Algorithm
- •1.8 Management
- •1.9 Conclusion
- •References
- •2.1 Introduction
- •2.2 Pathophysiology
- •2.3 Case Presentation
- •2.4 Case Discussion
- •2.5 Clinical Characteristics
- •1.7 Differential Diagnosis
- •2.6 Diagnostic Algorithm
- •2.7 Management
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Pathophysiology
- •3.3 Case Presentation
- •3.4 Case Discussion
- •3.5 Clinical Characteristics
- •3.6 Diagnostic Algorithm
- •3.7 Management
- •3.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Pathophysiology
- •4.3 Case Presentation
- •4.4 Case Discussion
- •4.6 Diagnostic Algorithm
- •4.7 Management
- •4.8 Conclusion
- •References
- •5.1 Introduction
- •5.2 Pathophysiology
- •5.3 Case Presentation
- •5.4 Case Discussion
- •5.5 Diagnostic Algorithm
- •5.6 Management
- •5.7 Conclusion
- •References
- •6.1 Introduction
- •6.2 Pathogenesis
- •6.3 Case Presentation
- •6.4 Case Discussion
- •6.5 Diagnostic Algorithm
- •6.6 Management
- •6.7 Conclusion
- •References
- •7.1 Introduction
- •7.2 Pathophysiology
- •7.3 Case Presentation
- •7.5 Differential Diagnosis
- •7.7 The Following Strategies Are Essential
- •7.7.1 Acute Symptom Relief
- •7.7.1.1 Pharmacological Treatment
- •7.7.2.1 Pharmacologic Prophylaxis
- •7.8 Conclusion
- •References
- •8.1 Introduction
- •8.3 Case Study
- •8.4 Case Discussion
- •8.5 Clinical Management
- •8.7 Diagnosis
- •8.8 Treatment
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Case Presentation
- •9.4 Diagnosis Algorithm
- •9.5 Secondary SUNCT
- •9.6 Management
- •9.8 Conclusion
- •References
- •10.1 Introduction
- •10.2 Pathophysiology
- •10.3 Case Presentation
- •10.4 Case Discussion
- •10.5 Clinical Characteristics
- •10.6 Diagnostic Algorithm
- •10.7 Management
- •10.8 Conclusion
- •References
- •11.1 Introduction
- •11.2 Pathophysiology
- •11.3 Case Presentation
- •11.4 Case Discussion
- •11.5 Clinical Characteristics
- •11.6 Diagnostic Algorithm
- •11.6.1 Step 1: Detailed Patient History
- •11.8 Management
- •11.9 Conclusions
- •12.2 Pathophysiology
- •12.3 Case Presentation
- •12.4 Case Discussion
- •12.6 Treatment
- •12.7 Conclusion
- •References
- •References
- •12.1 Introduction
- •13.1 Introduction
- •13.2 Pathophysiology
- •13.3 Case Presentation
- •13.4 Case Discussion
- •13.5 Clinical Characteristics
- •13.6 Diagnostic Algorithm
- •13.7 Management
- •13.8 Conclusion
- •References
- •14.1 Introduction
- •14.2 Pathophysiology
- •14.3 Case Presentation
- •14.3.1 Clinical Case 1
- •14.3.2 Clinical Case 2
- •14.4 Case Discussion
- •14.5 Clinical Characteristics
- •14.7 Treatment/Management
- •14.8 Conclusion
- •References
- •15.1 Introduction
- •15.2 Case Presentation
- •15.3 Case Discussion
- •15.4 Diagnostic Algorithm
- •15.5 Pathophysiology
- •15.6 Clinical Presentation
- •15.6.1 External-Compression Headache (ECH)
- •15.6.2 External-Traction Headache (ETH)
- •15.7 Management
- •15.7.1 Nonpharmacological Strategies
- •15.7.2 Pharmacological Strategies
- •15.7.3 Patient Education and Awareness
- •15.8 Conclusion
- •References
- •16.1 Introduction
- •16.2 Pathophysiology
- •16.3 Case Presentation
- •16.4 Case Discussion
- •16.6 Diagnostic Algorithm
- •16.7 Management
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Pathophysiology
- •17.3 Case Presentation
- •17.4 Case Discussion
- •17.5 Clinical Characteristics
- •17.6 Diagnosis
- •17.7 Differential Diagnosis
- •17.8 Treatment
- •17.9 Conclusion
- •References
- •18.1 Introduction
- •18.2 Pathophysiology
- •18.3 Case Presentation
- •18.4 Case Discussion
- •18.5 Clinical Presentation
- •18.6 Diagnosis
- •18.7 Differential Diagnosis
- •18.8 Treatment
- •18.9 Conclusion
- •References
- •19.1 Introduction
- •19.2 Pathophysiology
- •19.3 Case Presentation
- •19.4 Case Discussion
- •19.5 Diagnostic Approach
- •19.6 Management
- •19.7 Conclusion
- •References
- •20.1 Introduction
- •20.3 Case Report
- •20.4 Case Discussion
- •20.6 Clinical Presentation
- •20.7 Diagnostic Algorithm
- •20.8 Conclusion
- •References
- •21.1 Introduction
- •21.2 Case Presentation
- •21.3 Clinical Characteristics
- •21.4 Diagnosis
- •21.5 Treatment
- •References
- •22.1 Introduction
- •22.3 Case Presentation 1
- •22.4 Case Discussion
- •22.5 Case Presentation 2
- •22.6 Case Discussion 2
- •22.7 Clinical Characteristics
- •22.8 Diagnostic Workup
- •22.9 Treatment
- •22.10 Prognosis
- •References
- •23.1 Introduction
- •23.2 Pathophysiology
- •23.3 Case Presentation
- •23.4 Case Discussion
- •23.6 Diagnostic Algorithm
- •23.7 Management
- •23.8 Conclusion
- •References
- •24.1 Introduction
- •24.2 Case Presentation
- •24.3 Case Discussion
- •24.4 Pathophysiology
- •24.6 Clinical Characteristics
- •24.8 Treatment Approaches
- •24.10 Conclusion
- •References
- •25.1 Introduction
- •25.2 Case Presentation
- •25.3 Case Discussion
- •25.4 Conclusion
- •References
- •26.1 Introduction
- •26.2 Pathophysiology
- •26.3 Case Presentation
- •26.4 Case Discussion
- •26.5 Clinical Characteristics
- •26.6 Diagnostic Algorithm
- •26.7 Management
- •26.8 Conclusion
- •References
- •27.1 Introduction
- •27.2 Case Presentations
- •27.3 Clinical Characteristics
- •27.4 Discussion
- •27.5 Conclusion
- •References
- •28.1 Introduction
- •28.2 Case Presentation
- •28.3 Case Discussion
- •28.4 Clinical Characteristics
- •28.5 Diagnosis
- •28.6 Conclusion
- •28.7 Key Messages
- •References
- •29.1 Introduction
- •29.2 Pathophysiology
- •29.3 Case Presentation
- •29.4 Clinical Presentation
- •29.5 Diagnosis
- •29.6 Treatment
- •29.7 Conclusion
- •References
- •30.1 Introduction
- •30.2 Clinical Case
- •30.3 Clinical Presentation
- •30.4 Differential Diagnosis
- •30.5 Diagnosis
- •30.6 Treatment
- •30.7 Conclusion
- •References
- •31.1 Introduction
- •31.2 Pathophysiology
- •31.3 Case Presentation
- •31.4 Case Discussion
- •31.5 Clinical Presentation
- •31.7 Conclusion
- •References
- •32.1 Introduction
- •32.2 Pathophysiology
- •32.3 Case Presentation
- •32.4 Case Discussion
- •32.6 Diagnosis
- •32.7 Additional Diagnostic Evaluations
- •32.8 Apply ICHD-3 Diagnostic Criteria [9]
- •32.10 Management
- •32.11 Conclusion
- •References
- •33.1 Introduction
- •33.2 Pathophysiology
- •33.3 Case Presentation
- •33.4 Clinical Characteristics
- •33.5 Diagnostic Algorithm
- •33.6 Treatment
- •33.7 Conclusion
- •References
- •34.1 Introduction
- •34.2 Pathophysiology
- •34.3 Case Presentation
- •34.4 Case Discussion
- •34.6 Diagnostic Algorithm
- •34.7 Treatment
- •34.8 Conclusion
- •References
- •35.1 Introduction
- •35.3 Case Presentation
- •35.4 Case Discussion
- •35.7 Treatment
- •35.7.1 Oxygen Therapy (100% Oxygen)
- •35.8 Conclusion
- •References
- •36.1 Introduction
- •36.2 Pathophysiology
- •36.3 Case Presentation
- •36.5 Diagnostic Algorithm
- •36.6 Treatment
- •36.7 Conclusion
- •References
- •37.1 Introduction
- •37.2 Pathophysiology
- •37.3 Case Presentation
- •37.4 Headache Characteristics
- •37.5 Case Discussion
- •37.6 Treatment
- •37.7 Conclusion
- •References
- •38.1 Introduction
- •38.2 Pathophysiology
- •38.3 Case Presentation
- •38.4 Clinical Presentation
- •38.5 Diagnostic Algorithm
- •38.6 Treatment
- •38.7 Conclusion
- •References
- •39.1 Introduction
- •39.3 Case Presentation
- •39.4 Case Discussion
- •39.6 ICHD-3 Diagnostic Criteria [28]
- •39.6.1 Diagnostic Criteria
- •39.7 Diagnostic Algorithm
- •39.9 Conclusion
- •References
- •40.1 Introduction
- •40.3 Case Presentation
- •40.4 Case Discussion
- •40.5.1 Diagnostic Algorithm
- •40.6 Treatment
- •40.7 Conclusion
- •References
- •41.1 Introduction
- •41.3 Case Presentation
- •41.4 Clinical Presentation
- •41.5 Differential Diagnosis
- •41.6 Conclusion
- •41.7 Key Messages
- •References
- •42.1 Introduction
- •42.2 Pathophysiology
- •42.3 Case Presentation
- •42.5 Case Discussion
- •42.6 Clinical Presentation
- •42.7 Diagnostic Algorithm [9]
- •42.8 Preeclampsia
- •42.9 Eclampsia
- •42.10 Fetal Assessment
- •42.11 Treatment
- •42.12 Antihypertensive Management [8]
- •42.14 Conclusion
- •References
- •43.1 Introduction
- •43.2 Pathophysiology
- •43.3 Case Presentation
- •43.4 Case Discussion
- •43.5 Clinical Manifestations
- •43.6 Diagnosis
- •43.7 Treatment
- •43.8 Conclusion
- •References
- •44.1 Introduction
- •44.2 Pathophysiology
- •44.3 Case Presentation
- •44.4 Case Discussion
- •44.6 Diagnostic Approach
- •44.7 Management
- •44.8 Conclusion
- •References
- •45.1 Introduction
- •45.2 Pathophysiology
- •45.3 Case Presentation
- •45.6 Treatment
- •45.7 Conclusion
- •References
- •46.1 Introduction
- •46.2 Pathophysiology
- •46.3 Case Presentation
- •46.4 Clinical Characteristics
- •46.5 Differential Diagnosis
- •46.6 Treatment
- •46.7 Conclusion
- •References
- •47.1 Introduction
- •47.2 Pathophysiology
- •47.3 Case Presentation
- •47.4 Case Discussion
- •47.5 Clinical Presentations
- •47.6 Diagnostic Algorithm
- •47.7 Differential Diagnosis
- •47.8 Treatment
- •47.9 Conclusion
- •References
- •48.1 Introduction
- •48.2 Pathophysiology
- •48.3 Case Presentation
- •48.4 Case Discussion
- •48.5 Clinical Characteristics
- •48.7 Treatment
- •48.8 Conclusion
- •References
- •49.1 Introduction
- •49.2 Pathophysiology
- •49.3 Case Presentation
- •49.4 Clinical Presentation
- •49.5 Diagnosis
- •49.6 Treatment
- •49.7 Conclusion
- •References
- •50.1 Introduction
- •50.2 Pathophysiology
- •50.3 Case Presentation
- •50.4 Case Discussion
- •50.5 Clinical Characteristics
- •50.6 Diagnosis
- •50.7 Treatment
- •50.8 Conclusion
- •References
- •51.1 Introduction
- •51.2 Case Presentation
- •51.3 Clinical Characteristics
- •51.4 Diagnosis
- •51.5 Treatment
- •51.6 Conclusion
- •References
- •52.1 Introduction
- •52.2 Pathophysiology
- •52.3 Case Presentation
- •52.4 Case Discussion
- •52.5 Clinical Characteristics
- •52.6 Diagnosis
- •52.6.1 Cervicogenic Headache
- •52.6.2 Migraine
- •52.6.3 Neck Pain
- •52.6.4 Demyelinating Lesions
- •52.6.5 Cervical Myelitis
- •52.6.6 Occipital Allodynia
- •52.6.7 Cervical Muscle Spasms
- •52.7 Treatment
- •52.7.2 Acupuncture
- •52.7.3 Transcutaneous Electrical Nerve Stimulations (TENS)
- •52.8 Minimally Invasive Treatment
- •52.8.1 Nerve Blocks
- •52.8.2 Botulinum Toxin A
- •52.8.3 Radio Frequency
- •52.8.4 Occipital Nerve Stimulation
- •52.9 Surgical Treatments
- •52.10 Conclusions
- •References
- •53.1 Introduction
- •53.2 Pathophysiology
- •53.3 Characteristics of Pain
- •53.4 Case Presentation
- •53.5 Case Discussion
- •53.6 Clinical Characteristics
- •53.8 Treatment
- •53.9 Conclusion
- •References
- •54.1 Introduction
- •54.2 Pathophysiology
- •54.3 Case Presentation
- •54.4 Case Discussion
- •54.5 Clinical Characteristics
- •54.6 Diagnostic Algorithm
- •54.7 Management
- •54.8 Conclusion
- •References
- •55.1 Introduction
- •55.2 Pathophysiology
- •55.3 Case Presentation

29 Migraine-Like Aura Attributed toCerebral Amyloid Angiopathy (CAA)
275
visual and sensory symptoms—occurring in the absence of signicant headache—
was consistent with migraine-like aura attributed to CAA, a known but underrecognized manifestation of the disease.
29.4 Clinical Presentation
A retrospective study conducted between 2012 and 2018 investigated migraine
prevalence and symptomatology in patients with familial CAA (D-CAA), correlating migraine history with ICH onset, ICH location, and cSS presence on MRI.Among
86 carriers, 48 (56%) had a positive migraine history, mostly among women (60%).
According to ICHD-3 criteria, 39 (45%) had denite migraine, with all migraine
sufferers experiencing aura. Specically:
• 42% had only visual auras.
• 12% experienced additional sensory aura symptoms.
• 5% had additional aphasia.
• 24% had typical aura without headache, with 14% reporting this as their only
migraine attack type.
The age of onset for migraine with aura showed two peaks: one before the third
decade and another after the fourth decade. The prevalence of migraine in D-CAA
was signicantly higher for both men (51%) and women (59%) compared to the
general Dutch population (lifetime prevalence: 13% in men and 33% in women).
Notably, all D-CAA patients with migraine experienced visual aura. Single aura
symptoms lasting more than 60min were observed in 23% of patients. While prolonged aura is common in the general population, it is concerning in D-CAA carriers, as it indicates acute ICH in 55% of cases [4].
Migraine-like aura has been reported in rare monogenic cerebrovascular syndromes and may serve as an early hallmark or isolated symptom. Examples include
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, as well as retinal vasculopathy with cerebral leukoencephalopathy
and systemic manifestations. These ndings suggest a link between migraine and
microvascular changes during the early stages of angiopathies [5].
Numerous monogenic disorders may manifest with aura, occasionally presenting
as “true” migraine with aura, fullling ICHD-3 criteria. These disorders affect various biological pathways, including ion channels, vascular proteins, and mitochondrial metabolism, contributing to increased susceptibility to spreading
depolarization—an underlying mechanism of aura. Therefore, a distinct clinical
classication from typical migraine is warranted for patients with hereditary conditions, necessitating tailored management strategies [4, 5].

276
M. E. Nobre
29.5 Diagnosis
Neurological symptoms, such as cerebral hemorrhagic manifestations, transient
focal neurological episodes, memory clinic indicators, headache, or migraine-like
aura, must be considered [2, 4].
Imaging tests, including magnetic resonance imaging (MRI) and computed
tomography (CT) scans, are essential. Predominantly involving the small cortical
and leptomeningeal vessels, amyloid-β CAA can be identied in life by characteristic hemorrhagic structural imaging markers on blood-sensitive MRI sequences,
namely cortical supercial siderosis and lobar cerebral microbleeds. These hemorrhagic imaging markers, along with symptomatic bleeding events, such as parenchymal ICH and acute convexity subarachnoid hemorrhage, form the basis of the
diagnostic Boston criteria [2–4].
Other nonhemorrhagic imaging features, such as cerebral atrophy, white matter
hyperintensities, and MRI-visible perivascular spaces in the centrum semi-ovale
(CSO-PVS), are also commonly observed in sporadic CAA.Although these are not
necessarily specic to CAA, white matter hyperintensities in a “multispot” pattern
and CSO-PVS have been included in the most recent Boston criteria (Version 2.0).
There are also CT-based diagnostic criteria for CAA (the Edinburgh criteria); however, these require knowledge of the epsilon 4 allele (APOE ε4) genotype for complete application. Validation of using the imaging components alone is ongoing, but
early suggestions indicate that they do possess diagnostic accuracy [2–4].
As MRI is more widely used for the clinical assessment of various neurological
conditions, an increasing number of individuals are identied as having imaging
features of CAA, which can be incidental or unexpected ndings. Although clinical
context is essential for determining their signicance, in younger patients presenting with ICH, cognitive symptoms, or transient focal neurological episodes, the
presence of these markers may indicate certain rare but essential causes of CAA that
warrant specic and focused investigation, with implications for patients and their
families [2–4].
Amyloid-PET imaging can also be helpful. However, it is essential to recognize
that tracers can bind to other amyloids and are therefore not specic for amyloid-β [2].
Cerebrospinal uid (CSF) measurement of amyloid-β markers can be valuable, although validated thresholds for the clinical diagnosis of CAA have not yet
been established. The presence of CSF amyloid-β1–42 levels or a CSF
amyloid-β1–42/1–40 ratio consistent with Alzheimer’s disease would support a
diagnosis of cerebral beta-amyloidosis [2–4].
Genetic testing may also be necessary in the context of CAA.Hereditary forms
associated with mutations in genes like APP (amyloid precursor protein) or PSEN1/
PSEN2 (presenilin 1/2) could be identied through genetic testing, especially if
there is a family history suggesting genetic predisposition to CAA or early-onset
Alzheimer’s disease. Thus, genetic testing can help inform diagnosis and management for affected individuals [3–5].

29 Migraine-Like Aura Attributed toCerebral Amyloid Angiopathy (CAA)
Primary migraines can often present with aura symptoms (visual, sensory, or
speech-related) and may occur independently of CAA.A review of the differential
diagnosis of late-onset aura (LOA) indicates that TIAs, seizures, subarachnoid hemorrhage, arteriovenous malformation, dural arteriovenous stula, patent foramen
ovale, posterior circulation embolism, internal carotid artery dissection, vertebral
artery dissection, carotid artery stenosis, moyamoya disease, brain tumors, and
other rare disorders can also mimic migraine aura, in addition to CAA.Therefore,
the diagnosis of late-life migraine accompaniments should be made by exclusion
through appropriate investigations [3, 4, 6].
277
29.6 Treatment
The treatment of migraine-like aura associated with cerebral amyloid angiopathy
(CAA) primarily aims to manage symptoms and reduce the risk of complications,
as there is no specic therapy targeting the aura itself. Symptomatic treatment may
include standard migraine medications if the headache follows the aura, although
the aura itself typically does not respond to these treatments. Preventive strategies
focus on lifestyle modications such as maintaining proper hydration, ensuring
regular sleep patterns, and avoiding known migraine triggers like stress or certain
foods. It is also essential to control vascular risk factors—particularly hypertension,
hyperlipidemia, and diabetes—as these can exacerbate the underlying pathology
and increase the risk of cerebral hemorrhage or ischemic events.
In patients with CAA, the use of anticoagulants is generally avoided due to the
heightened risk of intracerebral bleeding, unless there is a compelling indication.
Education of the patient and family is a key part of the management strategy, emphasizing awareness of potential neurologic symptoms and the importance of promptly
reporting any new changes. Ongoing monitoring through regular neurologic follow up is crucial to evaluate disease progression and to adjust the treatment plan
as needed.
Ultimately, management should be individualized based on the frequency and
severity of aura episodes, the presence of associated headaches, and the patient’s
overall health status. A collaborative, multidisciplinary approach allows for a personalized care plan that addresses both the symptoms of migraine-like aura and the
complexities of cerebral amyloid angiopathy.
29.7 Conclusion
Migraine with aura is an important, often inaugural symptom of CAA.Aura attacks
lasting ≥60min may signal acute ICH in CAA.Migraine with aura may be regarded
as an early marker of disease in hereditary CAA, potentially preceding the occurrence of symptomatic ICH by several years [4]. Although mostly benign, late-onset

278
M. E. Nobre
aura (LOA) must be differentiated from secondary causes [6]. Blood-sensitive magnetic resonance imaging sequences are the best tools for the early detection of
underlying pathology; therefore, treatment with antiplatelet or anticoagulant drugs
should be avoided, as these may increase the risk of hemorrhage [6].
Management of patients with CAA and migraine-like symptoms focuses on
treating underlying risk factors, monitoring for complications, and sometimes
employing standard migraine treatments if warranted. However, caution is advised,
as specic migraine treatments may increase the risk of hemorrhage in patients with
CAA [6, 7].
References
1. Vinters HV.Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18(2):311–24. https://
doi.org/10.1161/01.str.18.2.311. PMID: 3551211.
2. Banerjee G, Collinge J, Fox NC, Lashley T, Mead S, Schott JM, Werring DJ, Ryan NS.Clinical
considerations in early-onset cerebral amyloid angiopathy. Brain. 2023;146(10):3991–4014.
https://doi.org/10.1093/brain/awad193.
3. Smith EE, Charidimou A, Ayata C, Werring DJ, Greenberg SM.Cerebral amyloid angiopathy-
related transient focal neurologic episodes. Neurology. 2021;97(5):231–8. https://doi.
org/10.1212/WNL.0000000000012234. Epub 2021 May 20. PMID: 34016709; PMCID:
PMC8356377.
4. Koemans EA, Voigt S, Rasing I, Van Etten ES, Van Zwet EW, Van Walderveen MAA,
Wermer MJH, Terwindt GM.Migraine with aura as early disease marker in hereditary Dutch-
type cerebral amyloid angiopathy. Stroke. 2020;51(4):1094–9. https://doi.org/10.1161/
STROKEAHA.119.028170.
5. Pensato U, Demchuk AM, Dreier JP, Brennan KC, Sacco S, Romoli M.Aura phenomenon: a
proposal for an etiology-based clinical classication. J Headache Pain. 2025;26(9):1–9. https://
doi.org/10.1186/s10194- 024- 01943- 8.
6. Samanci B, Coban O, Baykan B.Late onset aura may herald cerebral amyloid angiopathy: a
case report. Cephalalgia. 2016;36(10):998–1001. https://doi.org/10.1177/0333102415620253.
Epub 2015 Nov 26. PMID: 26611682.
7. Paterson RW, Uchino K, Emsley HC, Pullicino P. Recurrent stereotyped episodes in cere-
bral amyloid angiopathy: response to migraine prophylaxis in two patients. Cerebrovasc
Dis Extra. 2013;3(1):81–4. https://doi.org/10.1159/000347114. PMID: 23741226; PMCID:
PMC3670647.

Chapter 30
Headache Attributed toPituitary Apoplexy
CarolinaMartins , JesuínoAlbino , JulianaAndrade ,
andMarceloValença
30.1 Introduction
Apoplexy derives from a Greek root and means “a sudden blow.” In medicine, it is
used to characterize the sudden onset of a set of signals and symptoms (hence, a
syndrome), usually related to the infarction of hemorrhage of an organ or structure.
When no anatomical ndings accompany such a syndrome, the term functional apoplexy is applied.
Pituitary apoplexy, therefore, is a term used to describe a sudden constellation of
signs and symptoms related to endocrinological, visual, oculomotor, or meningeal
symptoms resulting from vascular changes (infarction, hemorrhage or both) within
the sellar content. Apoplexy happens in the context of adenomas, Rathke cysts and
several other pituitary lesions, including normal pituitary glands in especial conditions (pregnancy, puerperal period) [1]. Nevertheless, it is commonly seen in the
setting of an undiagnosed pituitary adenoma [2].
The incidence of apoplexy in pituitary adenomas when considering clinical and
surgical or histopathological evidence is 2–7% [3]. This combination of factors
must be differentiated from the ndings of hemorrhagic infarction in lesions harbored by asymptomatic patients which reach up to 25% [3]. This differentiation is
paramount because the latter does not conform with a diagnosis of pituitary
C. Martins (*) · J. Andrade · M. Valença
Department of Neuropsychiatry, Federal University of Pernambuco (UFPE), Recife, Brazil
e-mail: maria.cmlima@ufpe.br
J. Albino
Neurocirurgia Assistência e Ensino (NAE), Recife, Brazil
Switzerland AG 2026
D. Uludüz et al. (eds.), Rare Causes of Headache Disorders, Headache,
https://doi.org/10.1007/978-3-032-10242-3_30
279© The Author(s), under exclusive license to Springer Nature

280
C. Martins et al.
apoplexy. Pituitary apoplexy was rst described as a syndrome by Pearce Bailey, in
1898 [3], it received this denomination in 1950, by Brougham etal. [4].
Lesions of the sellar and parasellar regions are a common nding in the general
population and their incidental ndings on cadaveric and health volunteer imaging
studies vary from 1.7% to 27% [5]. On the other hand, headache as a presenting
complaint among patients with pituitary lesions range from 33% to 73%, consistently higher than the prevalence of headaches in the general population, meaning
that sellar lesions do cause headache—and in fact this is often the primary reason
leading to the diagnosis [5]. Because scant data exist on the specic improvement
of headache after surgical treatment of sellar/parasellar lesions, it remains challenging to indicate surgical resection in patients harboring these lesions—and no other
sign or symptom.
Among sellar lesions, adenomas are the most frequent, occurring in 20% of
the general population [6], from childhood to the elderly, and most of them
being incidental and asymptomatic (at the most 5% of adenomas are symptomatic) [5]. Adenomas can be classied by (a) size—as microadenomas (less
10mm), macroadenomas (more than 10mm), and giant macroadenomas (more
than 40mm in greatest dimension), (b) hormonal production—as functional and
non-functional, (c) histology, or (d) biologic behavior [6]. Among functional
adenomas, prolactinomas are the most frequent. Prolactinomas comprise 30%
of all adenomas, while nonfunctional adenomas correspond to another
25–30% [6].
This being said, apoplexy, therefore, occurs when a sellar structure—usually a
pituitary adenoma—undergoes hemorrhage, infarction, or both. Most cases affect
males (twice as likely to present with apoplexy) [7], during fth or sixth decade of
life, often on previously unidentied non-functional adenomas or prolactinomas.
Because apoplexy differs signicantly from the incidental nding of a sellar/
parasellar lesion during the investigation of a headache patient, the surgical considerations made above do not apply. It is fundamental to understand that apoplexy
results in a life-threatening situation with pressing goals that take precedence over
(but fortunately overlapping) with the relief of the headache.
30.2 Clinical Case
A 37-year-old male was transferred to a tertiary, neurovascular unit hours after
having presented himself at his district health unit, with a sudden and severe
headache, vomiting, and decrease in visual acuity. Although his admission
occurred two months into the ofcial coronavirus disease 2019 (COVID-19) pandemic period in our region—and at a time when no specic diagnostic tests were
available—suspected patients were in small numbers, community spread low, and
it was still possible to keep infected patients segregated within a part of our health

30 Headache Attributed toPituitary Apoplexy
281
network. The headache woke him out of sleep, and he experienced sudden vomiting at the installation of the complaints. Neurological examination at the emergency department showed Glasgow Coma Scale of 12 out of 15. He was restless
and anxious, complaining of a throbbing headache. He was not cushingoid, acromegalic, or eunuchoid and no gynecomastia or galactorrhea was present. Unable
to help with the bedside visual acuity test, the patient kept repeating that he could
not see well, especially with his left eye. There was a sluggish light reex bilaterally and a questionable nuchal rigidity. A subarachnoid hemorrhage was the initial diagnostic assumption, as no previous medical history of a sellar lesion
existed. A computed tomography (CT) scan (Fig.30.1A–D), however, showed an
enlarged sella and an intrasellar lesion that extended to the suprasellar space and
protruded towards the cavernous sinuses, particularly on the left. A bright, thin
halo on the top of the lesion suggested focal subarachnoid intracranial hemorrhage. The patient was admitted to the intensive care unit (ICU) with the diagnosis of apoplectic, previously undiagnosed sellar lesion and routine preoperative
exams as well as hormonal serum prole were collected. An endovenous (EV)
bolus of hydrocortisone 500mg was administered before surgery, while awaiting
the results of the hormonal prole. Five hours after admission he was taken to the
operating room (OR) and a microsurgical transsphenoidal surgery with endoscopic assistance performed. During surgery, the bony sellar oor was found
thinned and eroded, with a tense sellar dura prolapsing towards the sphenoidal
sinus. Dural opening initially relieved a liquied, reddish bloody content and further material was collected under the surgical microscope with transsphenoidal
microsurgical curettes. The endoscope was introduced to explore the cavity at the
end of the procedure and further laterally displaced material removed, except on
the right side, where the pituitary gland seemed to have been displaced. The sella
oor was closed using a bony fragment reserved from the sphenoidal rostrum during the approach, supported by Gelfoam cubes. The surgical procedure was
undertaken under 150minutes. At the immediate postop period, the patient indicated relief both of his headache and visual disturbances. The same-day postop
CT scan (Fig.30.1E–H), 17hours after the admission CT, showed adequate sellar
decompression. Preop serum prole disclosed only mild elevation of serum prolactin, compatible with infundibular compression by a non-secreting pituitary
adenoma, later conrmed by histopathology. The postop period was uneventful,
during which rst line, EV, analgesic drugs, were administered, when needed, and
were enough to control his headache. Oral hydrocortisone was swiftly tapered off
while monitoring the urinary density and output. The patient was able to perform
a campimetry on the third postop day. He was discharged on the fourth postop
day, after repetition of the hormonal prole and having the rst endocrinologic
outpatient consultation scheduled within a fortnight. The rst neurosurgical outpatient follow-up, scheduled in four weeks’ time included evaluation of postop
magnetic resonance imaging (MRI) and comparative campimetry.

282
C. Martins et al.
A
B
C
E
F
G
D
Fig. 30.1 (A–D) Emergency room (ER) admission, non-contrast CT scans on axial (A–C) and
sagittal (D) planes. A predominantly hyperdense sellar lesion extended to the suprasellar area (a).
A hyperdense halo is seen around the edges of the lesion. The oor of the III ventricle and infundibulum cannot be seen on the sagittal view, but the subarachnoid cisterns are opened (b), and the
sulci and gyri can be delineated, suggesting an absence of signicant elevation of global intracranial pressure. The oor of the sella did not—at rst—seem thinned, but it was found during surgery to be eroded and breached, with a tense, bulging sellar dura protruding into the sphenoid sinus
(c) suggesting increase intrasellar pressure. (E–H). Postoperative, non-enhanced CT scan obtained
17hours after admission. Adequate debulking of the lesion has been achieved, but for a small
remnant on the right of the sella that seemed particularly stuck during surgery. With decompression
of the sella, the oor of the III ventricle and infundibulum (d) could then be seen (H).
H

30 Headache Attributed toPituitary Apoplexy
283
30.3 Clinical Presentation
Typically, signs and symptoms of pituitary apoplexy start abruptly with (a) headache, (b) vomiting and (c) disturbance in consciousness, (d) visual disturbance
(visual loss, eld defects or ophthalmoplegia), and (e) acute hypopituitarism [6].
Signs and symptoms associated with pituitary apoplexy may have different proposed pathogenesis (Box30.1).
The resulting syndrome may be mild but often presents as a catastrophic event
and may be initially attributed to stroke or subarachnoid hemorrhage [2], resulting
that these patients will often be seen in neurovascular reference centers—as happened in the index-case, presented above.
Pituitary apoplexy was the clinical manifestation that led to the diagnosis of a
pituitary lesion in more than 80% of cases [3] and in up to 97.4% of patients [4].
Box 30.1 Signs and symptoms associated with pituitary apoplexy and their proposed
pathogenesis
Headache Intrasellar contents
Nausea and
vomiting
Visual eld
defects
Reduced
visual acuity
Reduced level
of
consciousness
rapidly increase in
size leading to dural
stretching
Pain is transmitted
through meningeal
nerves supplying the
central skull base dura
With headache and
altered consciousness,
nausea and vomiting
can be part of
intracranial
hypertensive
syndrome
Optic nerve, chiasm,
or tract impingement
by upward
displacement of
intrasellar contents
As a part of CNII
decit syndrome can
be cause by optical
apparatus
Displacement
With headache,
nausea, and vomiting
can be part of
intracranial
hypertensive
syndrome
Sellar wall
enlargement causes
displacement of the
superior division of
the trigeminal nerve
(CNV1) within the
cavernous sinus
Can signal adrenal
insufciency
Due to hypothalamic
involvement
With vomiting and
altered consciousness, the
headache can be part of
intracranial hypertensive
syndrome that can be due
to enlargement of sellar
contents only, to
subarachnoid hemorrhage
or obstructive
hydrocephalus
Can signal hypothalamic
dysfunction
Due to adrenal
insufciency

284
C. Martins et al.
Although headache is described as the earliest symptom [3], present in most
(84–89.8%) [5, 8] or all patients [9] with apoplexy—while visual loss and ophthalmoparesis are only described in 52–57% of the patients at presentation [9, 10]—the
type, localization, and severity of the headache are seldom detailed.
The literature available mentions sudden and severe headache that can be retroorbital, bifrontal, or diffuse [3] and combined with nausea and vomiting. Apoplexy
patients usually describe a signicant short duration of the headache (1–10days)
than the non-apoplexy patients harboring sellar lesions (4days–30years) [5].
Cranial nerve palsy may involve III, IV, and VI, and usually signal the extension
of apoplectic tumor to a specic cavernous sinus compartment [11–13]. In the case
of early III nerve involvement, superolateral expansion may displace the nerve,
which is located horizontally in the same plane as the pituitary gland [10] and
against its entry dural point (the oculomotor porus) at the cavernous sinus oculomotor trigone [14]. An ischemic cranial nerve syndrome can also result from compression of dural arteries supplying the transdural, cavernous segments of these nerves.
Because these vessels arise at the cavernous segment of the internal carotid artery
and also supply the meningeal layers in the central skull base [15] a similar pathophysiology can explain the headache and ophthalmoparesis in apoplectic patients.
Hypopituitarism is usually considered when there is proof of biochemical deciency of at least one endocrine axis. When prolactin is elevated, a differentiation
should be made between the elevation related to infundibular compression of the
pituitary stalk which decreases dopamine inhibition to the pituitary gland (levels of
less than 250 ng/mL) and an elevation that signals a prolactin-secreting tumor
(higher than 1000ng/mL) [16].
Patients with pituitary apoplexy and low serum prolactin at presentation are
deemed to have the highest intrasellar pressure and be prone to poor recovery [3]
after decompressive surgery, making their management even more time pressing,
explaining the expedite treatment offered to our case-example.
Secondary electrolyte abnormalities and acid–base imbalance are usually responsible for other life-risking ndings as arrhythmia [17], but bradycardia may result
from distortion of III ventricular walls and resulting hypothalamic dysfunction.
Acute secondary adrenal insufciency is seen in approximately two-third of apoplectic patients and can be a major source of mortality [3]. Hypocortisolemia renders vasculature less responsive to pressor effects of catecholamines, which results
in hemodynamic instability. It also augments vasopressin release from the posterior
pituitary lobe inhibiting water excretion and resulting in dilution hyponatremia.
Particularly in patients undergoing surgery and additional metabolic requirements,
prompt empirical corticosteroid replacement should be undertaken, with hydrocortisone intravenously at rst, but orally as soon as viable and possible. If the oral
route remains closed, the intramuscular route should be elected instead, because of
the saturation kinetics of cortisol binding globulin [3]. Once recovered from acute
stress, the hydrocortisone should be quickly tapered. For biochemically-proven
insufcient-patients, a standard maintenance dose is 20–30mg per day, orally, usually divided into three doses, and reevaluation of adrenocorticotropic hormone
(ACTH) reserve reassessed at three months follow-up [3].
Соседние файлы в папке Библиотека им академика М.И. Перельмана
